Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04245748 · ClinicalTrials.gov registry record · Phase 4
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
A Phase 4 study of Depression and Anxious Depression, sponsored by University of Cincinnati.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT04245748 is a Phase 4 study of Depression and Anxious Depression that is actively recruiting participants, run by University of Cincinnati. The registered enrollment target is 84 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04245748, a Phase 4 study of Depression and Anxious Depression, is actively recruiting participants, sponsored by University of Cincinnati.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by double-blind, randomized adjunctive treatment with clonazepam or pregabalin for persistent symptoms.
Conditions Studied
Interventions
- DRUG Duloxetine
- DRUG Escitalopram
Study Locations (1)
Ohio
- University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2020-03-01 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04245748
The ClinicalTrials.gov registry entry for NCT04245748 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (89% lower). The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Duloxetine is the first listed.
NCT04245748 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT04245748 about?
NCT04245748 is a clinical study titled "Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)". Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by double-blind, randomized adjunctive treatment with clonazepam or pregabalin for persistent symptoms.
What is the current status of trial NCT04245748?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 84 participants. The study started on 2020-03-01. Estimated completion is 2025-12-31.
What conditions does trial NCT04245748 study?
This clinical trial studies the following conditions: Depression, Anxious Depression.
What interventions are being tested in trial NCT04245748?
The interventions under investigation include: Duloxetine (DRUG), Escitalopram (DRUG).
Who is sponsoring clinical trial NCT04245748?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04245748 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
-
Dopaminergic Therapy for Anhedonia - 2
RECRUITING · Phase 4
-
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
RECRUITING · Phase 4
-
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
RECRUITING · Phase 4
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.